Literature DB >> 26010239

Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS.

Kimberly L Garrison1, Selma Sahin1,2, Leslie Z Benet1.   

Abstract

This study was conducted to determine the number of drugs exhibiting flip-flop pharmacokinetics following oral (p.o.) dosing from immediate-release dosage forms and if they exhibit a common characteristic that may be predicted based on BDDCS classification. The literature was searched for drugs displaying flip-flop kinetics (i.e., absorption half-life larger than elimination half-life) in mammals in PubMed, via internet search engines and reviewing drug pharmacokinetic data. Twenty two drugs were identified as displaying flip-flop kinetics in humans (13 drugs), rat (nine drugs), monkey (three drugs), horse (two drugs), and/or rabbit (two drugs). Nineteen of the 22 drugs exhibiting flip-flop kinetics were BDDCS Classes 3 and 4. One of the three exceptions, meclofenamic acid (Class 2), was identified in the horse; however, it would not exhibit flip-flop kinetics in humans where the p.o. dosing terminal half-life is 1.4 h. The second, carvedilol, can be explained based on solubility issues, but the third sapropterin dihydrochloride (nominally Class 1) requires further consideration. The few drugs displaying p.o. flip-flop kinetics in humans are predominantly BDDCS Classes 3 and 4. New molecular entities predicted to be BDDCS Classes 3 and 4 could be liable to exhibit flip-flop kinetics when the elimination half life is short and should be suspected to be substrates for intestinal transporters.
© 2015 Wiley Periodicals, Inc. and the American Pharmacists Association.

Entities:  

Keywords:  BDDCS; absorption; disposition; flip-flop pharmacokinetics; half-life; intestinal absorption; oral drug absorption; pharmacokinetics; transporters

Mesh:

Substances:

Year:  2015        PMID: 26010239      PMCID: PMC4536115          DOI: 10.1002/jps.24505

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  69 in total

1.  The pharmacokinetics of nedocromil sodium, a new drug for the treatment of reversible obstructive airways disease, in human volunteers and patients with reversible obstructive airways disease.

Authors:  M G Neale; K Brown; R A Foulds; S Lal; D A Morris; D Thomas
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

2.  Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects.

Authors:  S M Singhvi; H Y Pan; R A Morrison; D A Willard
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

3.  Pharmacokinetics and bioavailability of carbovir, a carbocyclic nucleoside active against human immunodeficiency virus, in rats.

Authors:  Y H Yeom; R P Remmel; S H Huang; M Hua; R Vince; C L Zimmerman
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

4.  Pharmacokinetics and bioavailability of zidovudine in humans.

Authors:  M R Blum; S H Liao; S S Good; P de Miranda
Journal:  Am J Med       Date:  1988-08-29       Impact factor: 4.965

5.  Pharmacokinetics of xamoterol after intravenous and oral administration to volunteers.

Authors:  W Bastain; M J Boyce; L E Stafford; P B Morton; D A Clarke; H F Marlow
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Existence of a flip-flop kinetic model for zidovudine (AZT) after oral administration.

Authors:  G C Melvin; S R Ellison; C M Monk; T R Bates
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1990-11

7.  Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases.

Authors:  R W Klecker; J M Collins; R Yarchoan; R Thomas; J F Jenkins; S Broder; C E Myers
Journal:  Clin Pharmacol Ther       Date:  1987-04       Impact factor: 6.875

8.  Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker.

Authors:  E von Möllendorff; K Reiff; G Neugebauer
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  The metabolism and excretion of carbovir, a carbocyclic nucleoside, in the rat.

Authors:  J S Walsh; J E Patanella; S E Unger; K R Brouwer; G T Miwa
Journal:  Drug Metab Dispos       Date:  1990 Nov-Dec       Impact factor: 3.922

10.  Pharmacokinetics and saturable renal tubular secretion of zidovudine in rats.

Authors:  B A Patel; C K Chu; F D Boudinot
Journal:  J Pharm Sci       Date:  1989-07       Impact factor: 3.534

View more
  5 in total

Review 1.  BDDCS Predictions, Self-Correcting Aspects of BDDCS Assignments, BDDCS Assignment Corrections, and Classification for more than 175 Additional Drugs.

Authors:  Chelsea M Hosey; Rosa Chan; Leslie Z Benet
Journal:  AAPS J       Date:  2015-11-20       Impact factor: 4.009

2.  Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers.

Authors:  E Wenzler; E J Ellis-Grosse; K A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

3.  Dose-dependent bioavailability, absorption-rate limited elimination, and tissue distribution of the ATR inhibitor BAY-1895344 (elimusertib) in mice.

Authors:  Brian F Kiesel; Joshua J Deppas; Jianxia Guo; Robert A Parise; David A Clump; Christopher J Bakkenist; Jan H Beumer
Journal:  Cancer Chemother Pharmacol       Date:  2022-05-04       Impact factor: 3.288

Review 4.  BDDCS, the Rule of 5 and drugability.

Authors:  Leslie Z Benet; Chelsea M Hosey; Oleg Ursu; Tudor I Oprea
Journal:  Adv Drug Deliv Rev       Date:  2016-05-13       Impact factor: 15.470

5.  Anti-Rift Valley fever virus activity in vitro, pre-clinical pharmacokinetics and oral bioavailability of benzavir-2, a broad-acting antiviral compound.

Authors:  Md Koushikul Islam; Mårten Strand; Michael Saleeb; Richard Svensson; Pawel Baranczewski; Per Artursson; Göran Wadell; Clas Ahlm; Mikael Elofsson; Magnus Evander
Journal:  Sci Rep       Date:  2018-01-31       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.